Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $8.4 million.

  • Kiniksa Pharmaceuticals International's Change in Accured Expenses fell 2248.98% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year decrease of 2408.87%. This contributed to the annual value of $43.7 million for FY2024, which is 15814.05% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Change in Accured Expenses of $8.4 million as of Q3 2025, which was down 2248.98% from $13.1 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Change in Accured Expenses' 5-year high stood at $18.7 million during Q2 2024, with a 5-year trough of -$10.6 million in Q1 2023.
  • Its 5-year average for Change in Accured Expenses is $4.5 million, with a median of $4.1 million in 2022.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Change in Accured Expenses crashed by 45686.98% in 2022 and then surged by 34594.91% in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Change in Accured Expenses stood at $10.0 million in 2021, then tumbled by 137.74% to -$3.8 million in 2022, then soared by 239.44% to $5.3 million in 2023, then soared by 107.96% to $11.0 million in 2024, then decreased by 23.88% to $8.4 million in 2025.
  • Its Change in Accured Expenses stands at $8.4 million for Q3 2025, versus $13.1 million for Q2 2025 and -$3.6 million for Q1 2025.